Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients


30 Sep 2019


Poster Display session 3


Tumour Site

Prostate Cancer


Anouk de Jong


Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248


A.C. de Jong1, M. Segbers2, M. Smits3, T. Brabander2, R. de Wit1, N. Mehra3, A.A.M. Van der Veldt1, M.P. Lolkema1

Author affiliations

  • 1 Department Of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 2 Department Of Radiology And Nuclear Medicine, Erasmus MC, 3015 GD - Rotterdam/NL
  • 3 Department Of Medical Oncology, Radboud University Medical Center, 6525 GA - Nijmegen/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4058


For individual treatment planning in patients with metastatic castration resistant prostate cancer (mCRPC), molecular analyses are increasingly used. As most patients have bone only disease, bone biopsies are often the only source for tumour tissue. However, the success rate of computed tomography (CT)-guided bone biopsies for molecular analyses in mCRPC patients is only 36.5-44%. Positron emission tomography (PET) using 68Ga-PSMA is a promising tool to increase the success rate of bone biopsies for molecular analyses in mCRPC patients.


In this multicenter study, the success rate of 68Ga-PSMA guided bone biopsies for molecular diagnostics was retrospectively evaluated in a subset of mCRPC patients who underwent a bone biopsy for whole-genome DNA sequencing within the CPCT-02 study (NCT01855477). To evaluate whether biopsies were obtained from a 68Ga-PSMA positive lesion, rigid body image registration of 68Ga-PSMA PET/CT and interventional CT was performed. This technique provided volume of interest (VOI) based quantification of 68Ga-PSMA uptake at the exact biopsy site. In addition, the potential impact of molecular analyses on clinical decision making was evaluated.


Sixty-nine 68Ga-PSMA-guided biopsies were eligible for primary analysis. Based on tumor percentage ≥ 30%, 70% of 68Ga-PSMA-guided biopsies was eligible for molecular analyses. At biopsy sites with positive, inconclusive or negative 68Ga-PSMA uptake, tumour percentage was ≥ 30% in 73%, 55% and 36% of the biopsies, respectively (p = 0.0850). At sites of biopsies with a tumour percentage ≥ 30%, standardized uptake value (SUV)max and SUVmean of 68Ga-PSMA were significantly higher (p = 0.0260 and p = 0.0129 respectively), whereas Hounsfield units (HU)mean and HUmax on CT were significantly lower (p = 0.0189 and p = 0.0494 respectively). Molecular analyses identified potentially targetable aberrations including PTEN loss, AR amplifications, and BRCA variants.


68Ga-PSMA PET/CT is a useful technique to improve the success rate of CT-guided bone biopsies for molecular analyses in mCRPC patients. Successful bone biopsies for molecular analyses can improve individual treatment planning by detecting targetable mutations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


R. de Wit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: Clovis. N. Mehra: Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Genzyme; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer. A.A.M. Van der Veldt: Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: MSD; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Sanofi; Honoraria (institution), Advisory / Consultancy: Ipsen. M.P. Lolkema: Research grant / Funding (institution): JNJ; Research grant / Funding (institution): Astellas. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.